Percutaneous ethanol injection for hepatocellular carcinoma: 20‐year outcome and prognostic factors

Abstract

BackgroundEthanol injection is the best-known image-guided percutaneous ablation for hepatocellular carcinoma (HCC) and a well-tolerated, inexpensive procedure with few adverse effects. However, there have been few reports on its long-term results.AimsWe report a 20-year consecutive case series at a tertiary referral centre.MethodsWe performed 2147 ethanol injection treatments on 685 primary HCC patients and analysed a collected database.ResultsFinal computed tomography demonstrated complete ablation of treated tumours in 2108 (98.2%) of the 2147 treatments. With a median follow-up of 51.6 months, 5-, 10- and 20-year survival rates were 49.0% [95% confidence interval (CI) = 45.3–53.0%], 17.9% (95% CI = 15.0–21.2%) and 7.2% (95% CI = 4..5–11.5%) respectively. Multivariate analysis demonstrated that age, Child–Pugh class, tumour size, tumour number and serum alpha-fetoprotein level were significant prognostic factors for survival. Five-, 10- and 20-year local tumour progression rates were 18.2% (95% CI = 15.0–21.4%), 18.4% (95% CI = 15.2–21.6%) and 18.4% (95% CI = 15.2–21.6%) respectively. Five-, 10- and 20-year distant recurrence rates were 53.5% (95% CI = 49.4–57.7%), 60.4 (95% CI = 56.3–64.5%) and 60.8% (95% CI = 56.7–64.9%) respectively. There were 45 complications (2.1%) and two deaths (0.09%).ConclusionsEthanol injection was potentially curative for HCC, resulting in survival for more than 20 years. This study suggests that new ablation therapies will achieve similar or even better long-term results in HCC.